LTZ Therapeutics, a Palo Alto, CA and Shenzhen, China-based biotech company, raised $17M in Pre-Series A funding.
The round was led by K2 Venture Partners, with participation from Qiming Venture Partners and Tigermed.
The company intends to use the funds to develop its three-pronged platform, establish its initial pipeline and to further build the operations team.
Co-founded by seasoned drug developers Robert Li Ph.D, Martin Treder Ph.D and Jianhui Zhou Ph.D., LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. It is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging biology of tumor microenvironment.